---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-23-000003"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T03:08:37.901439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead Q4 2022 rev $7.4B, EPS $1.30; ex-Veklury sales +9%; FY 2023 guidance $26.0-26.5B product sales

## Summary
- Q4 revenue $7.4B (+2%); product sales ex-Veklury +9% to $6.3B.
- GAAP diluted EPS Q4 $1.30 vs $0.30; non-GAAP $1.67 vs $0.69.
- FY 2022 Biktarvy sales $10.4B (+20%); Trodelvy $680M (+79%); Cell Therapy $1.5B (+68%).
- FY 2023 guidance: product sales $26.0-26.5B; GAAP EPS $5.30-5.70; non-GAAP EPS $6.60-7.00.
- Q4 operating cash flow $2.6B; dividends $916M; share repurchases $791M.

## SEC filing metadata
- accession: 0000882095-23-000003
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/0000882095-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/gild-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-23-000003
- JSON: https://secwatch.observer/filing/0000882095-23-000003.json
- Plain text: https://secwatch.observer/filing/0000882095-23-000003.txt

## Key facts
- Earnings Releases
  GILEAD SCIENCES, INC. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 2, 2023 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882095/000088209523000003/0000882095-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.